title: Preventive effects of enzyme-treated rice fiber in a restraint stress-induced irritable bowel syndrome model.
abstract: Irritable bowel syndrome (IBS) is a common health issue that is characterized by abdominal pain, abnormal bowel movements, altered visceral perception, and abnormal metabolism of 5-hydroxy triptamine (serotonin; 5HT). The use of prebiotics or probiotics treatment for IBS has become increasingly important as an adjunct to pharmaceutical options. The aim of this study was to determine the efficacy of enzyme-treated rice fiber (ERF) on an IBS model. We obtained a new prebiotic from defatted rice bran that was developed as an insoluble dietary fiber through amylase and hemicellulase treatment followed by removal of the soluble fraction. Containing approximately 70% hemicellulose, ERF is utilized by lactobacilli and subsequently converted to butyrate using Eubacterium limosum. We employed a restraint stress IBS model which involved the continuous application of stress for 4 h per day for 3 days. Polycarbophil Ca (PC) (500 mg/kg body weight) was used as a positive control and ERF was added to the diet at 4% in diet. During restraint stress, ERF significantly attenuated urgent fecal excretion, colonic mucosal 5HT secretion, and hyperalgesthesia compared with the control. ERF also significantly increased cecal butyrate production as well as total organic acid content. PC was only effective in regard to preventing increases in 5HT levels. Furthermore, there were no significant levels of pro-inflammatory markers CINC-1 and TNF-alpha among the groups. Although more detailed studies are needed, the ERF prebiotic demonstrated potency in attenuating major symptoms of IBS.
authors.affiliation: Central Laboratories for Frontier Technology, Kirin Holdings Co. Ltd., Kanazawa-ku, Yokohama, 236-0004, Japan. kanauchio@kirin.co.jp
authors.forename: Osamu
authors.initials: O
authors.lastname: Kanauchi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Mitsuyama
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Komiyama
authors.forename: Minoru
authors.initials: M
authors.lastname: Yagi
authors.forename: Akira
authors.initials: A
authors.lastname: Andoh
authors.forename: Michio
authors.initials: M
authors.lastname: Sata
mesh_terms: D000681:Amylases / Q000378:metabolism*; D000818:Animals; D001835:Body Weight; D002264:Carboxylic Acids / Q000378:metabolism; D054360:Chemokine CXCL1 / Q000378:metabolism; D004043:Dietary Fiber / Q000378:metabolism*; D004195:Disease Models, Animal; D005243:Feces; D005247:Feeding Behavior; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology; D043183:Irritable Bowel Syndrome / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D012275:Oryza / Q000378:metabolism*; D017288:Pain Threshold; D051381:Rats; D017207:Rats, Sprague-Dawley; D012149:Restraint, Physical; D012701:Serotonin / Q000378:metabolism; D012995:Solubility; D013312:Stress, Physiological; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D002264:Carboxylic Acids; D054360:Chemokine CXCL1; C513297:Cxcl1 protein, rat; D004043:Dietary Fiber; D014409:Tumor Necrosis Factor-alpha; D012701:Serotonin; D000681:Amylases